Accuray makes radiation therapy systems, planning software and imaging tools for hospitals and cancer centers. It last closed at $2.44 on Nov 17, down 4.31% on the day. ARAY reports earnings on Wed, Feb 3, 2027.
ARAY · as of the Nov 17 close · updated after every close
Uptrend, overbought
The stock is 53% above its 20 day and 76% above its 50 day average. It is 82% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 67), overbought. The nearest support is the Pivot S1 at $2.32, and the nearest resistance the Pivot at $2.51.
Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 14.5%/day
Key levels
$4.0552 week high+66.0%
$4.05Swing high (Nov 9)+66.0%
$2.63Pivot R1+7.8%
$2.51Pivot+2.9%
$2.44Last close
$2.32Pivot S1−4.9%
$1.1420 day average−53.3%
$0.6050 day average−75.4%
$0.43100 day average−82.4%
$0.43200 day average−82.4%
$0.31Swing low (Jun 11)−87.3%
$0.1152 week low−95.5%
Indicators
RSI (14)
67.24
Strong, overbought above 70
Neutral
MACD
0.70
Above its signal line
Bullish
Stochastic
63.1
Middle of its range
Neutral
ADX (14)
37.0
Trending up
Williams %R
-40.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
67.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+1559.9%
Change over 10 sessions
Bullish
ATR (14)
$0.35
Typical daily range, 14.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend, overbought
Short trendBullish
Long trendBearish
MomentumStrong
StretchOverbought
VolatilityHigh, 14.8%/day
Key levels
$4.0552 week high+66.0%
$4.05Swing high (Nov 9)+66.0%
$2.63Pivot R1+7.8%
$2.51Pivot+2.9%
$2.44Last close
$2.32Pivot S1−4.9%
$1.1420 day average−53.3%
$0.6050 day average−75.4%
$0.43100 day average−82.4%
$0.43200 day average−82.4%
$0.31Swing low (Jun 11)−87.3%
$0.1152 week low−95.5%
Indicators
RSI (14)
80.17
Overbought above 70
Overbought
MACD
0.26
Above its signal line
Bullish
Stochastic
42.8
Middle of its range
Neutral
ADX (14)
31.6
Trending up
Williams %R
-40.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
290.2
Oversold below −100, overbought above 100
Overbought
Rate of change
+875.2%
Change over 10 sessions
Bullish
ATR (14)
$0.36
Typical daily range, 14.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ARAY
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ARAY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ARAY usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARAY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARAY is in one of them and how their past ARAY trades turned out.
Accuray is a radiation therapy company based in Madison, Wisconsin. It makes radiation treatment systems, including the CyberKnife robotic platform and a range of helical systems, along with treatment planning software, imaging technology and related services such as installation, training and customer support. Its customers include hospitals, cancer centers and clinicians, including radiation oncologists and neurosurgeons, who use the equipment to treat tumors and selected neurologic or endocrine disorders where clinically appropriate.